Meeting News
No dose-limiting toxicities occurred in patients with relapsed/refractory multiple myeloma who were treated with agenT-797...
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.
A large analysis of real-world treatment outcomes in patients with myelofibrosis who were treated with ruxolitinib.
Momelotinib led to “superior” symptom and spleen responses and transfusion independence rates compared to danazol.
As TKIs have become available to patients, survival for those with CML has significantly improved but disparities.
VERIFY, a phase III trial of the hepcidin mimetic rusfertide (PTG-300), is now enrolling patients with PV.
IFN alpha-2 influences the regulation of several ECM genes involved in tissue remodeling.
Does the route of administration matter in preventing CNS relapse in agressive B-cell lymphomas?
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes and efficacy in patients ...
Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting.
Dr. Coombs discussed these challenges during the 10th Annual Meeting of the Society of Hematologic Oncology.
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL).
Jia Ruan, MD, PhD, discusses emerging treatment options for mantle cell lymphoma at the 2022 SOHO Annual Meeting.
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Assistant Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2022 Mashup Media, LLC. All rights reserved.